Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280293 | 0.88 | LMNA (0.56) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL880429 | 0.87 | SMN1; SMN2 (0.64) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL880490 | 0.84 | LMNA (0.62) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL880231 | 0.83 | MAPT (0.68) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL880388 | 0.81 | LMNA (0.66) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL13522427 | 0.78 | HSD17B10 (0.53) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL852442 | 0.78 | LMNA (0.72) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL880249 | 0.77 | MAPT (0.58) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL880302 | 0.77 | LMNA (0.65) | LMNAALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL14047471 | 0.77 | LMNA (0.67) | LMNAALDH1A1TDP1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | LMNA 525/4885ALDH1A1 171/4885TDP1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.